Pure Global AI
NCT06304805Completed

TGRX-326 Phase I/II Pharmacokinetic Study

A Randomized, Open-label, Single-dose, 3-cycle, 6-sequence, Crossover Study Evaluating Food Effect on Pharmacokinetic Profiles of TGRX-326 in Chinese Healthy Subjects and Effect of Drug Specification on Bioavailability in Human
Shenzhen TargetRx, Inc.Phase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Non Small Cell Lung Cancer
Drug/Device/Intervention
cycle 1: treatment drug
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Shenzhen TargetRx, Inc.
Location
Bengbu, China
Timeline & enrollment
Phase
Phase 1
Start date
Dec 13, 2023
End date
Jan 19, 2024
Enrollment
24 participants
Primary outcome

Plasma Cmax,Plasma AUC(0-t),Plasma AUC(0-inf)

Summary

A study evaluating the effects of food intake on the pharmacokinetic (PK) profiles of
 TGRX-326 and the effect of different drug specifications on human bioavailability for
 TGRX-326, a drug indicated for non-small cell lung cancer treatment

ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06304805
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06304805 through Pure Global AI's free database. This Phase 1 trial is sponsored by Shenzhen TargetRx, Inc. and is currently Completed. The study focuses on Non Small Cell Lung Cancer. Target enrollment is 24 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.